Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 20, 2022
Deals

Dec. 19 Quick Takes: Sanofi, Innate deepen ties with NK licensing deal

Plus: FDA hold on Entrada’s DMD treatment and updates from Atara, AZ, LianBio-Pfizer, F2G, Protillion, and more 
BioCentury | Aug 27, 2021
Distillery Therapeutics

Enhancing NK cell cancer therapies with bispecific antibodies

BioCentury | Jul 30, 2021
Emerging Company Profile

Cytovia: activating NK cells at the tumor site

Emerging Company Profile: With its R&D center up and running and a manufacturing facility by year-end, Cytovia aims to enter the clinic early 2022
BioCentury | May 1, 2021
Product Development

NK cell engagers gain traction on broader bispecifics momentum

NK cell engagers emerge as a budding innate immune modality in immuno-oncology’s second wave
BioCentury | Apr 8, 2020
Product Development

COVID-19 roundup: U.S. to freeze WHO funding as Wellcome calls on CEOs to support $8B fund; plus Ridgeback-Emory, Karyopharm, IQVia and more

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Aug 29, 2017
Distillery Therapeutics

Hematology

BioCentury | Aug 11, 2017
Preclinical News

Study links FNAIT miscarriages to NK cells

BioCentury | Mar 3, 2017
Emerging Company Profile

Dragonfly’s trinkets

How Dragonfly's trispecific antibodies could boost antitumor NK cell activity
Items per page:
1 - 10 of 22